Implant Sciences to Exhibit at Transportation Security Expo 2013 in London
WILMINGTON, Mass., Nov. 12, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it will present its QS-H150 handheld explosives trace detector and its QS-B220 desktop explosives and drugs trace detector at Transport Security Expo 2013 in London at the Olympia on November 13th and 14th at booth # K20. Over 3,000 international attendees and 108 global exhibitors from 65 nations are expected to participate in the expo.
The Transport Security Expo has been a leading event for global heads of aviation, maritime, counter piracy, public transport and supply chain security for the past 10 years. Designed to deliver clarity to the complex task of protecting passengers, cargo and high risk assets from those intent on doing harm, Transport Security Expo is one of the world's most established events in this arena.
"This will be our second time exhibiting at Transport Security Expo. After a successful first time exhibition, we feel that we are even better positioned this year to translate our participation directly into sales. Our QS-B220's recent STAC certification for civil aviation security in France as well as recent TSA qualification for air cargo screening positions us to capitalize on the opportunities offered by Transport Security Expo," stated Implant Sciences' President and CEO, Glenn D. Bolduc.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than competing products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. The Company is the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. In addition to receiving TSA qualification, the QS-B220 has received STAC certification and a Qualified Anti-Terrorism Technology Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). Implant Sciences' QS-H150 handheld explosives trace detector has also received a Qualified Anti-Terrorism Technology Designation under the SAFETY Act. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact:
Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700
or
Investor Contact:
Laurel Moody
646-810-0608
SOURCE Implant Sciences Corporation
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article